The metabolism of Clopidogrel can be decreased when combined with Ticagrelor. The risk or severity of adverse effects can be increased when Fluvoxamine is combined with Clopidogrel. The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Lacidipine. Clopidogrel may increase the anticoagulant activities of Danaparoid. The metabolism of Cyclophosphamide can be decreased when combined with Clopidogrel. The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Benidipine. The metabolism of Clopidogrel can be decreased when combined with Ziprasidone. The risk or severity of adverse effects can be increased when Clopidogrel is combined with Carbaspirin calcium. Clopidogrel may increase the anticoagulant activities of Phenindione. The metabolism of Velpatasvir can be decreased when combined with Clopidogrel. The metabolism of Artemether can be decreased when combined with Clopidogrel. The risk or severity of adverse effects can be increased when Clopidogrel is combined with Salicylic acid. The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Diltiazem. The metabolism of Temazepam can be decreased when combined with Clopidogrel. The metabolism of Clopidogrel can be decreased when combined with Quinine. The metabolism of Clopidogrel can be decreased when combined with Tolbutamide. Clopidogrel may increase the anticoagulant activities of Acenocoumarol. The risk or severity of adverse effects can be increased when Clopidogrel is combined with Aminosalicylic Acid. The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Fendiline. The risk or severity of adverse effects can be increased when Clopidogrel is combined with Diflunisal. Resveratrol may increase the anticoagulant activities of Clopidogrel. The metabolism of Brompheniramine can be decreased when combined with Clopidogrel. Clopidogrel may increase the anticoagulant activities of Ancrod. Alprostadil may increase the anticoagulant activities of Clopidogrel. The serum concentration of Clopidogrel can be decreased when it is combined with Lumacaftor. The serum concentration of Clopidogrel can be decreased when it is combined with Bosentan. The metabolism of Clopidogrel can be decreased when combined with Valproic Acid. Ketanserin may increase the anticoagulant activities of Clopidogrel. The risk or severity of adverse effects can be increased when Ibrutinib is combined with Clopidogrel. The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Sarilumab. Clopidogrel may increase the anticoagulant activities of Fluindione. The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Azelnidipine. The risk or severity of adverse effects can be increased when Clopidogrel is combined with Methyl salicylate. Milrinone may increase the anticoagulant activities of Clopidogrel. The metabolism of Ropivacaine can be decreased when combined with Clopidogrel. The metabolism of Clopidogrel can be decreased when combined with Clarithromycin. The metabolism of Clopidogrel can be increased when combined with Primidone. The metabolism of Loperamide can be decreased when combined with Clopidogrel. The serum concentration of Clopidogrel can be increased when it is combined with Fusidic Acid. Tesmilifene may increase the anticoagulant activities of Clopidogrel. The metabolism of Clopidogrel can be decreased when combined with Sorafenib. The metabolism of Clopidogrel can be decreased when combined with Telithromycin. The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Tetrahydropalmatine. Clopidogrel may increase the anticoagulant activities of Ethyl biscoumacetate. The metabolism of clomethiazole can be decreased when combined with Clopidogrel. Clopidogrel may increase the anticoagulant activities of Astaxanthin. Ramatroban may increase the anticoagulant activities of Clopidogrel. Omega-3 fatty acids may increase the antiplatelet activities of Clopidogrel. The risk or severity of adverse effects can be increased when Clopidogrel is combined with Trolamine salicylate. Glucosamine may increase the antiplatelet activities of Clopidogrel. Ifetroban may increase the anticoagulant activities of Clopidogrel. The metabolism of Ritonavir can be decreased when combined with Clopidogrel. Iloprost may increase the antiplatelet activities of Clopidogrel. The metabolism of Tramadol can be decreased when combined with Clopidogrel. The serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Lobeglitazone resulting in a loss in efficacy. Clopidogrel may increase the anticoagulant activities of Letaxaban. The serum concentration of Clopidogrel can be decreased when it is combined with Mitotane. Clopidogrel may increase the anticoagulant activities of Ozagrel. Clopidogrel may increase the anticoagulant activities of Anagrelide. Clopidogrel may increase the anticoagulant activities of Desmoteplase. Clopidogrel may increase the anticoagulant activities of Gabexate. The risk or severity of adverse effects can be increased when Limaprost is combined with Clopidogrel. The risk or severity of adverse effects can be increased when Clopidogrel is combined with Aloxiprin. Clopidogrel may increase the anticoagulant activities of Edoxaban. The metabolism of Clopidogrel can be decreased when combined with Floxuridine. The serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Nicardipine resulting in a loss in efficacy. The metabolism of Ketamine can be decreased when combined with Clopidogrel. Trapidil may increase the anticoagulant activities of Clopidogrel. The metabolism of Pethidine can be decreased when combined with Clopidogrel. The metabolism of Clopidogrel can be decreased when combined with Azithromycin. The metabolism of Clopidogrel can be decreased when combined with Boceprevir. Clopidogrel may increase the anticoagulant activities of Protein C. The metabolism of Domperidone can be decreased when combined with Clopidogrel. The metabolism of Halothane can be decreased when combined with Clopidogrel. The metabolism of Dextromethorphan can be decreased when combined with Clopidogrel. The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Amrinone. The serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Rucaparib resulting in a loss in efficacy. Clopidogrel may increase the anticoagulant activities of Dextran 75. The metabolism of Clopidogrel can be decreased when combined with Idelalisib. The serum concentration of Clopidogrel can be increased when it is combined with Fosaprepitant. The metabolism of Clopidogrel can be decreased when combined with Zafirlukast. The metabolism of Clopidogrel can be decreased when combined with Dosulepin. The metabolism of Clopidogrel can be decreased when combined with Cobicistat. Clopidogrel may increase the anticoagulant activities of Alteplase. The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Niludipine. The serum concentration of Repaglinide can be increased when it is combined with Clopidogrel. The metabolism of Seratrodast can be decreased when combined with Clopidogrel. The metabolism of Nicotine can be decreased when combined with Clopidogrel. The metabolism of Clopidogrel can be decreased when combined with Lopinavir. The metabolism of Clopidogrel can be decreased when combined with Crisaborole. Clopidogrel may increase the anticoagulant activities of Defibrotide. The serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Sertraline resulting in a loss in efficacy. Clopidogrel may increase the anticoagulant activities of Bemiparin. The serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Indinavir resulting in a loss in efficacy. The serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Ticlopidine resulting in a loss in efficacy. Clopidogrel may increase the anticoagulant activities of Reviparin. The risk or severity of adverse effects can be increased when Clopidogrel is combined with Olsalazine. The metabolism of Clopidogrel can be decreased when combined with Midostaurin. The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Nisoldipine. The metabolism of Ixazomib can be decreased when combined with Clopidogrel. The metabolism of Clopidogrel can be decreased when combined with Valsartan. The serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Amiodarone resulting in a loss in efficacy. Clopidogrel may increase the anticoagulant activities of Edetic Acid. The risk or severity of adverse effects can be increased when Clopidogrel is combined with Tositumomab. The metabolism of Clopidogrel can be increased when combined with Secobarbital. Clopidogrel may increase the anticoagulant activities of Selexipag. The serum concentration of Clopidogrel can be increased when it is combined with Stiripentol. The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Darodipine. The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Magnesium Sulfate. The serum concentration of Clopidogrel can be increased when it is combined with Vemurafenib. The risk or severity of adverse effects can be increased when Rifabutin is combined with Clopidogrel. Clopidogrel may increase the anticoagulant activities of Protein S human. Clopidogrel may increase the anticoagulant activities of Fibrinolysin. The serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Eslicarbazepine acetate resulting in a loss in efficacy. The serum concentration of Clopidogrel can be decreased when it is combined with Siltuximab. The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Xylometazoline. The metabolism of Clopidogrel can be increased when combined with Phenobarbital. The serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Delavirdine resulting in a loss in efficacy. The metabolism of Clopidogrel can be decreased when combined with Telaprevir. The serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Isoniazid resulting in a loss in efficacy. Morphine may decrease the antiplatelet activities of Clopidogrel. Clopidogrel may increase the anticoagulant activities of Ferulic acid. The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Isradipine. The serum concentration of Clopidogrel can be increased when it is combined with Ranolazine. The metabolism of Clopidogrel can be increased when combined with Nevirapine. The serum concentration of Clopidogrel can be decreased when it is combined with St. John's Wort. The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Naftopidil. The serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Dexlansoprazole resulting in a loss in efficacy. The metabolism of Clobazam can be decreased when combined with Clopidogrel. The metabolism of Clopidogrel can be increased when combined with Pentobarbital.